Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.
about
Perspectives on menopause and women with HIVNevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected PatientsRisk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentDrug interactions and antiretroviral drug monitoring.Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measuresInfluence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patientsHigher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.The protease inhibitors and HIV-associated bone loss.Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimensPlasma tenofovir trough concentrations are associated with renal dysfunction in Japanese patients with HIV infection: a retrospective cohort studyp16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.Bone Loss in HIV Infection.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.Out of focus: tailoring the cascade of care to the needs of women living with HIV.Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy.Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines.Changes in Urinary Biomarkers Over 10 Years Is Associated With Viral Suppression in a Prospective Cohort of Women Living With HIV.Brief Report: Cumulative Tenofovir Disoproxil Fumarate Exposure is Associated With Biomarkers of Tubular Injury and Fibrosis in HIV-Infected Men.Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety.Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India.Cohort Profile: The Women's Interagency HIV Study (WIHS).What do we know about tailoring treatment with tenofovir?British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q26772852-E162BA0E-4D4A-4850-9CD2-8EAB9B312435Q28548003-D69DFF1F-FFEC-4E54-9427-819671472E5AQ28554081-2EF58FCA-6E32-4E1B-834D-A67481D0DDA8Q34021173-CE601F86-819E-4DEA-ABD3-4ABCD561EB50Q34675000-508A269C-0281-4101-9E12-66FE2E037370Q35607723-0EAA67CA-6328-4866-B8F7-3B6D531C7DA9Q36663586-0669A63B-B389-4C30-A757-145A215180BAQ36818259-80D4EA10-BF76-489F-BB44-B13BA562AE0EQ37263602-9100794E-8432-4CA1-81B5-3EFFB0C67720Q37278399-59D53977-3EF8-4C32-99B4-029AD3E29A36Q37660709-AC741002-EC0F-46E2-B018-50DB38191749Q38835028-DE24CB4C-8139-4E30-950C-B5A68E11FE8FQ38954109-1B9FA712-6528-4C59-BE3F-F6A961B65D13Q39074109-6A6BAE92-4ADD-4D06-B93D-DC9B840E57BCQ40062892-4927F866-4204-4284-B14E-88111C158008Q40103229-02AADF49-AD4A-4F6D-AA2C-7D37D34C6AD2Q40219167-FD429A0D-5E7D-43B5-BF1A-C3AC04C08041Q40396204-2A91DB66-8CE9-4FE9-AFDB-DD1DA547146EQ40462001-DCD17DA3-3A76-415C-90CF-9B39F4747E0AQ40498380-D1DFE8B5-9602-49D2-8D01-35E48FF699B0Q40710519-ADC7157A-69C9-48A2-951E-F3020542846CQ45326406-A2A74D98-5A34-4112-907F-283F8BB5F131Q47633560-F2187934-87CF-41D6-9903-B48899C5812EQ52641469-96E8D890-6063-40B4-9441-760CA5E9FCC7Q54229338-BF254511-ECAF-4135-B663-B72D1300479DQ54624919-20933BA4-020D-4E3D-B3FF-2429D656A0CEQ57180790-7DEB2738-00E6-4715-AE23-1FA860065148
P2860
Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Common clinical conditions - a ...... cohort of HIV-infected women.
@en
Common clinical conditions - a ...... cohort of HIV-infected women.
@nl
type
label
Common clinical conditions - a ...... cohort of HIV-infected women.
@en
Common clinical conditions - a ...... cohort of HIV-infected women.
@nl
prefLabel
Common clinical conditions - a ...... cohort of HIV-infected women.
@en
Common clinical conditions - a ...... cohort of HIV-infected women.
@nl
P2093
P2860
P1433
P1476
Common clinical conditions - a ...... cohort of HIV-infected women.
@en
P2093
Howard Minkoff
Kathryn Anastos
Mardge Cohen
Mary Young
Monica Gandhi
Peter Bacchetti
Rebecca Scherzer
Ruth M Greenblatt
Sanjiv M Baxi
Yong Huang
P2860
P356
10.1097/QAD.0000000000000033
P407
P577
2014-01-01T00:00:00Z